KEVZARA 150 mg,solution injectable en stylo prérempli 2 pens of 1.14 ml
Active ingredients: Sarilumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 pens of 1.14 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KEVZARA 150 mg,solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 stylos préremplis en verre à usage unique de 1,14 ml
- Marketing authorisation holder
- SANOFI WINTHROP INDUSTRIE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Sept 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63820638CIP73010062CIP133400930100622Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SARILUMABsolution | 150 mg · un stylo prérempli | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.